Angiogenesis is an essential mechanism for tumor development and proliferation. In the last decade,
inhibition of this mechanism has shown mostly encouraging results in different types of cancers. Urogenital
cancers (Prostate, Bladder, Testis and Kidney) represent approximately 25% of all diagnosed cancers
in both sexes and much effort has been made in order to incorporate anti-angiogenic agents in the treatment
of these cancers.
Inhibition of angiogenesis is the cornerstone of therapy in Renal Cell Carcinoma and has shown somewhat
promising results in prostate cancer. However, studies in both Urothelial carcinoma and Germ Cell Tumors remain mostly
In this paper, we report the landmark trials evaluating anti-angiogenic drugs in uro-genital cancers.